头孢地尔在治疗广泛和泛耐药鲍曼不动杆菌引起的复杂感染中的同情用药。
Cefiderocol for compassionate use in the treatment of complicated infections caused by extensively and pan-resistant Acinetobacter baumannii.
机构信息
Department of Public Health and Infectious Diseases, Sapienza University of Rome, Italy.
Department of Public Health and Infectious Diseases, Sapienza University of Rome, Italy.
出版信息
J Glob Antimicrob Resist. 2020 Dec;23:292-296. doi: 10.1016/j.jgar.2020.09.019. Epub 2020 Oct 13.
OBJECTIVE
This study presents real-life experience with cefiderocol used on a compassionate basis for treatment of three patients with severe infections caused by extensively/pan-drug resistant (XDR/PDR) Acinetobacter baumannii (Ab).
METHODS
Serum bactericidal activity was determined and considered as a surrogate of cefiderocol susceptibility.
RESULTS
Clinical improvement and microbiological eradication of A. baumannii were observed in all three patients, who were affected by extremely complex conditions either for type of infection, adverse effect or resistance profile of A. baumannii.
CONCLUSION
Cefiderocol for XDR/PDR-Ab infections might be reconsidered, especially in light of the recent disappointing results of the CREDIBLE-CR study.
目的
本研究介绍了使用头孢地尔在同情用药基础上治疗三例由广泛/全耐药（XDR/PDR）鲍曼不动杆菌（Ab）引起的严重感染患者的真实临床经验。
方法
测定血清杀菌活性并将其视为头孢地尔敏感性的替代指标。
结果
所有三名患者的临床状况均得到改善，且鲍曼不动杆菌的微生物学清除率均为阳性，这三名患者的感染类型、不良反应或鲍曼不动杆菌耐药情况都极其复杂。
结论
尤其是鉴于最近 CREDIBLE-CR 研究令人失望的结果，对于 XDR/PDR-Ab 感染，可能需要重新考虑使用头孢地尔。
Zotero 插件